Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose?

Akito Kume

doi:10.2147/ndt.s30160

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

This page is a summary of: Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose?, Neuropsychiatric Disease and Treatment, February 2014, Taylor & Francis,
DOI: 10.2147/ndt.s30160.
You can read the full text:

Read

Resources

Video
Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose?
Video abstract of review paper "Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose?" to be published in the open access journal Neuropsychiatric Disease and Treatment by Akito Kume.

Contributors

The following have contributed to this page

Dr Akito Kume
KUME Clinic

Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose?

Resources